Why the study?
Left atrial or left atrial appendage thrombosis carries a higher risk of thromboembolic events in atrial fibrillation, but the optimal antithrombotic strategy is not established.
Do novel oral anticoagulants improve the resolution of left atrial/left atrial appendage thrombosis compared to warfarin in patients with left atrial thrombosis?
Do novel oral anticoagulants improve the resolution of left atrial/left atrial appendage thrombosis compared to warfarin in patients with left atrial thrombosis?
Answers are grounded in this paper and cite their sources.
Novel oral anticoagulants are more effective than warfarin in promoting the resolution of left atrial/left atrial appendage thrombosis, without increasing the risks of bleeding or stroke.
The presence of left atrial/left atrial appendage thrombosis is associated with a higher risk of thromboembolic events in patients with atrial fibrillation. The optimal antithrombotic strategy is not established to date. Our aim was to compare the efficacy and safety profile of novel oral anticoagulants with warfarin in the treatment of left atrial/left atrial appendage thrombosis. We conducted a systematic search in PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and 3 Chinese databases for all randomized controlled trials and cohort studies (PROSPERO, CRD42021238952) from inception to 7 May 2021. Two authors independently performed the articles selection, data extraction, and quality assessment. The efficacy outcome was the resolution of left atrial/left atrial appendage thrombosis, and the safety outcomes were bleeding and stroke/transient ischemic attack. One randomized controlled trial and 5 cohort studies were included, with a total of 353 patients. Compared with warfarin, novel oral anticoagulants were associated with increased probability of left atrial/left atrial appendage thrombosis resolution (OR = 2.20; 95% CI, 1.35–3.60; I2 = 0%). Compared with warfarin, novel oral anticoagulants had a similar risk of bleeding (OR = 0.91; 95% CI, 0.39–2.13; I2 = 0%). There was no evidence of increased risk of stroke/transient ischemic attack (OR = 0.42; 95% CI, 0.12–1.45; I2 = 0%). Novel oral anticoagulants were more effective than warfarin in promoting the resolution of left atrial/left atrial appendage thrombosis, without increased risks of bleeding and stroke/transient ischemic attack. Our study provides valuable insight into clinical practice. Further well-designed randomized controlled trials are needed to fully evaluate the benefits and risks in these patients. PROSPERO Registration No.: CRD42021238952.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: